SCHEMBL5716201

SCHEMBL5716201

CC1(C)CC(=O)N(c2ccc(OC(=O)N3CCN(CCc4c[nH]cn4)CC3)nc2)C(=O)C1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.36
PKM P14618 1/20 0.33
AOC3 Q16853 3/20 0.32
KCNH2 Q12809 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
TP53 P04637 1/20 0.31
HRH2 P25021 1/20 0.31
HRH1 P35367 1/20 0.31
HTR1A P08908 2/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
POLB P06746 1/20 0.30
DRD2 P14416 1/20 0.30
HTR2A P28223 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715533 0.86 HTR1A (0.35) CYP4F2HTR1AMEN1KMT2APOLB
SCHEMBL5714878 0.86 TP53 (0.44) KCNH2SIGMAR1CYP2D6CYP2C19TP53
SCHEMBL6102543 0.86 CYP4F2 (0.34) CYP4F2PKMAOC3KCNH2SIGMAR1
SCHEMBL5714763 0.86 CYP4F2 (0.36) CYP4F2PKMAOC3KCNH2SIGMAR1
SCHEMBL6103192 0.84 KCNH2 (0.36) CYP4F2PKMKCNH2SIGMAR1CYP2D6
SCHEMBL5714669 0.84 KMT2A (0.36) CYP4F2PKMKCNH2SIGMAR1MEN1
SCHEMBL6102846 0.83 CYP4F2 (0.35) CYP4F2PKMKCNH2SIGMAR1HRH2
SCHEMBL5715472 0.82 ALDH1A1 (0.36) CYP4F2CYP2D6MEN1ALDH1A1KMT2A
SCHEMBL6102575 0.82 HTR1A (0.39) CYP4F2SIGMAR1HTR1AALDH1A1POLB
SCHEMBL6099834 0.82 CYP3A4 (0.39) CYP4F2PKMKCNH2SIGMAR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL CYP4F2 1228/4885PKM 2060/4885AOC3 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.